Loren Data's FBO Daily™

fbodaily.com
Home Today's FBO Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF SEPTEMBER 11, 2003 FBO #0653
SOLICITATION NOTICE

65 -- Oral Fluoroquinolones

Notice Date
9/9/2003
 
Notice Type
Solicitation Notice
 
Contracting Office
Attn: Department of Veterans Affairs National Acquisition Center, (049A1), P.O. Box 76, Building No. 37, Hines, Illinois 60141
 
ZIP Code
60141
 
Solicitation Number
797-NC-03-0035
 
Response Due
10/21/2003
 
Archive Date
11/19/2003
 
Point of Contact
Contracting Officer - John Callahan, Contract Specialist, (708) 786-5855
 
E-Mail Address
Email your questions to John Callahan
(john.callahan3@med.va.gov)
 
Description
Desc: The VA National Acquisition Center will issue Solicitation RFP-797-NC-03-0035, for the Dept. of Veterans Affairs (VA) and Dept. of Defense (DoD) for Oral Fluoroquinolones. A comprehensive drug class review was completed and resulted in a decision that only three agents could meet the requirements for use in the treatment of community acquired pneumonia (CAP) and sinusitis. The following three drugs met the criteria set by the Medical Advisory Panel, VISN Formulary Leaders, Pharmacy Benefit Management Group, and the Pharmacoeconomic Center: Gatifloxacin, Levofloxacin, and Moxifloxacin. The VA dispensed approximately 4.5 million doses and the DoD 4.4 million doses annually of the oral fluoroquinolones: gatifloxacin, levofloxacin, and moxifloxacin, combined. The oral fluoroquinolone market is expected to grow between 40% and 50% annually. The VA and DoD will place the awarded agent on the VA National Formulary and the DoD Basic Core Formulary as a ?workhorse? fluoroquinolone for the treatment of community acquired pneumonia (CAP), sinusitis, and other infections when clinically appropriate. The VA and DoD will mandate that all users of oral fluoroquinolone therapy for new episodes of CAP or sinusitis be placed on the contracted agent as initial therapy, unless medical necessity warrants a different initial choice. The VA and DoD will allow the placement of additional oral fluoroquinolone to facility formularies based on local susceptibility patterns. Indian Health Service and Bureau of Prisons may submit additional requirements, but the solicitation will clearly state whether these two agencies are included, and if so, what their additional annual usage is expected to be. The contract period will be for a period of one year, plus four, one-year options. Distribution will be through the VA?s and DoD?s Prime Vendor(s). The solicitation will be available for downloading on or about Sep 17, ?03, at the VA Office of Acquisition and Materiel Management?s Internet site at http://www.va.gov/oa&mm/busopp/sols.htm. Offers will be due on or about Oct 13, ?03. If a hard copy of this solicitation is desired please fax your request to John Callahan, at (708) 786-5256, or e-mail request to john.callahan3@med.va.gov, and a copy will be sent to you when it issues.
 
Web Link
RFP 797-NC-03-0035
(http://www.bos.oamm.va.gov/solicitation?number=797-NC-03-0035)
 
Record
SN00429788-W 20030911/030909213149 (fbodaily.com)
 
Source
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2016, Loren Data Corp.